Skip to main content
. 2008 May;19(3):219–226. doi: 10.1155/2008/161835

Figure 4.

Figure 4

Incremental costs and per cent of patients surviving at 98 days for voriconazole versus conventional amphotericin B (CAB)/fluconazole (FLU). Points to the right of the y-axis indicate voriconazole is more effective than CAB/FLU. Points below the x-axis indicate voriconazole is less costly than CAB/FLU. ICER Incremental cost-effectiveness ratios